Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Todd Foley
AddedFeb 15, 2024
UpdatedMay 31, 2026
Todd Foley

Todd Foley

Board Member, Tetherex Pharmaceuticals

CrunchbaseThe Org

Todd Foley's Career

Tetherex Pharmaceuticals
Tetherex Pharmaceuticals

Oklahoma City, OK, US

Board Member· Board
Iconic Therapeutics
Iconic Therapeutics

South San Francisco, CA, US

Board Member· Board
Aktis Oncology
Aktis Oncology

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Todd Foley's Career

Tetherex Pharmaceuticals
Tetherex Pharmaceuticals
Series B$53.3M302014Oklahoma City, OK, US
Board Member· Board

Leadership at Tetherex Pharmaceuticals

Scott RollinsScott RollinsBoard Member
Rodger P. McEverRodger P. McEverBoard Member
Richard D. CummingsRichard D. CummingsCo-Founder

Similar to Tetherex Pharmaceuticals

TherapyxTherapyxBuffalo, NY, USBiotechnologyTherapyxBuffalo, NY, US

Buffalo-based TherapyX is a private biotech firm specializing in innovative development-stage solutions.

Seed · $2.8M11
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30
XTuit PharmaceuticalsXTuit PharmaceuticalsWaltham, MA, USPharmaceuticalsest. 2011XTuit PharmaceuticalsWaltham, MA, US · est. 2011

XTuit Pharmaceuticals, based in Massachusetts, innovates in cancer therapy through targeted pharmaceutical development.

Series A · $26M30
Exalys TherapeuticsExalys TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2018Exalys TherapeuticsSan Diego, CA, US · est. 2018

Exalys Therapeutics develops novel anti-inflammatory drugs, targeting diseases with limited treatments.

Series A · $15M32
Iconic Therapeutics
Iconic Therapeutics
Acquired$82.8M02002South San Francisco, CA, US
Board Member· Board

Leadership at Iconic Therapeutics

Johan KördelJohan KördelBoard Member
Bruce RobertsonBruce RobertsonBoard Member
Kirk DornbushKirk DornbushCo-Founder
Dr K Peter HirthDr K Peter HirthBoard Member
Michael ShermanMichael ShermanCo-Founder
Bill GreeneBill GreeneCEO

Similar to Iconic Therapeutics

Eikon TherapeuticsEikon TherapeuticsHayward, CA, USBiopharmaceuticalsest. 2019Eikon TherapeuticsHayward, CA, US · est. 2019

Eikon Therapeutics: A biopharmaceutical firm innovating novel treatments for critical diseases.

Series C · $772M374
Imagen BiotechImagen BiotechNew York City, NY, USTherapeuticsest. 2011Imagen BiotechNew York City, NY, US · est. 2011

Imagen Biotech: Pioneering solutions for blinding diseases through innovative therapeutics.

Series A · $40M30
IkariaIkariaHampton, NJ, USPharmaceuticalsest. 2006IkariaHampton, NJ, US · est. 2006

Ikaria, Inc. innovates and patents novel therapeutic pharmaceuticals.

Series D · $344.9M750
ComplexaComplexaPittsburgh, PA, USTherapeuticsest. 2008ComplexaPittsburgh, PA, US · est. 2008

Complexa, Inc.: A biopharmaceutical firm innovating therapies for inflammatory and metabolic diseases.

Public · $86.9M7
Aktis Oncology
Aktis Oncology
Series A$156M432021Boston, MA, US
Board Member· Board

Recent news

Hopeful hearts and other startup newsTechCrunch · 2024

Leadership at Aktis Oncology

Matthew RodenMatthew RodenBoard Member
Brian GoodmanBrian GoodmanFounder

Todd Foley's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Todd Foley

Luke EvninLuke EvninBoard Member · DigiTx PartnersMatt RodenMatt RodenBoard Member · CelgeneEd HurwitzEd HurwitzBoard Member · MacroGenicsTommy StadlenTommy StadlenCo-Founder · Giant VenturesDan GulickDan GulickCo-Founder · Aspen PowerAndy TongAndy TongBoard Member · SyncFab